The Conference Forum presents the third annual Immuno-Oncology 360°, an event combining business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology (IO) clinical trials.
Designed by lead advisors, Dr. Axel Hoos (GSK) and Dr. James Gulley (NCI), the conference provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data to help accelerate clinical trials and FDA approval, transforming the way cancer is treated.
SITC member, Dr. James Allison, will participate as the keynote speaker during the event.
With the rapid development of cancer immunotherapy drug development, breakthrough FDA approval status, and fast-tracking clinical trials, competition in the space is fierce. The science behind immune-based therapies is driving rapid change. Both small and large companies are racing to bring game-changing therapies to the market and in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities.
Click here to view the full conference agenda.
#Oncologist #Collaboration #2017 #Researcher